Werewolf Therapeutics
- Founded: 2019
- Location: Watertown, MA
- Employee range: 11 - 50
- Clinical stage: Clin1b
- Therapy area: Oncology
- Drug types: ONC, IMM
- Lead product: WTX-124
- Product link: https://werewolftx.com/our-pipeline/
- Funding: $120M IPO Apr 2021; $72M B Jan 2021; $56M A Nov 2019
werewolftx.com linkedin.com job board
Short description:
Cancer Treatments
Drug notes:
WTX-330 Clin1 oncology; WTX-613 Clin0 oncology; WTX-712 RD tumors; Indukine molecules RD immuno-oncology, autoimmune and inflammatory disease
Long description:
Werewolf Therapeutics is pioneering conditionally activated macrophage therapies for the treatment of cancer. Their work revolves around PREDATOR, a proprietary platform that designs and engineers macrophages to specifically target and destroy cancer cells. PREDATOR macrophages are activated selectively within the tumor microenvironment, minimizing off-target effects and maximizing therapeutic impact. Werewolf Therapeutics' lead product candidates, WTX-124 and WTX-330, are conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. These therapies leverage the inherent tumor-fighting abilities of macrophages to effectively target and eliminate cancer cells while minimizing systemic toxicity.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com